Facebook
Twitter
ВКонтакте
Telegram
Сообщить о неточностиКвартальный отчет 2024-Q3
добавлен 13.11.2024
AcelRx Pharmaceuticals Мультипликаторы 2011-2024 | ACRX
Мультипликаторы по годам AcelRx Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.7 | 0.1 | -0.1 | -4.6 | -2.6 | -3.0 | -1.8 | -2.7 | -6.6 | -8.7 | -19.9 | -3.4 | -2.3 |
P/S |
18.8 | 2.7 | 1.0 | 34.6 | 59.5 | 66.8 | 11.4 | 6.8 | 8.3 | 55.8 | 15.8 | 47.3 | 43.5 |
EPS |
-1.3 | 5.7 | -5.9 | -0.5 | -0.7 | -0.8 | -1.1 | -0.9 | -0.6 | -0.8 | -0.6 | -1.5 | -1.2 |
EV (Enterprise Value) |
12.8 млн | 15.1 млн | 109 млн | 282 млн | 254 млн | 172 млн | 151 млн | 143 млн | 147 млн | 271 млн | 414 млн | 96 млн | 62.2 млн |
EBITDA per Share |
-1.16 | -3.2 | -5.67 | -0.459 | -0.663 | -0.602 | -0.788 | -0.66 | -0.389 | -0.847 | -0.153 | -1.32 | -1.09 |
EV/EBITDA |
-3.0 | -4.7 | -2.8 | -1.9 | -1.6 | -2.0 | -4.2 | -7.0 | -64.5 | -2.8 | -3.1 | ||
PEG |
-0.0 | 0.0 | -0.0 | -0.16 | -0.15 | -0.12 | 0.11 | 0.04 | -0.23 | 0.29 | -0.33 | 0.11 | -0.02 |
P/B |
0.9 | 0.2 | -0.1 | -3.4 | -3.3 | 33.8 | -2.5 | -22.1 | 4.8 | 6.2 | 6.4 | 3.3 | 2.7 |
P/CF |
-0.7 | -0.2 | -0.1 | -4.6 | -2.5 | -4.8 | -2.8 | -3.6 | -7.5 | -7.3 | -123.4 | -4.5 | -2.7 |
ROE % |
-130.43 | 218.92 | 97.79 | 72.43 | 128.54 | -1108.61 | 141.08 | 808.64 | -73.68 | -71.49 | -32.02 | -98.57 | -115.07 |
ROA % |
-90.20 | 100.56 | -45.06 | -60.91 | -58.28 | -39.12 | -68.18 | -43.16 | -19.09 | -38.58 | -21.29 | -51.71 | -49.22 |
ROCE % |
-119.74 | -115.98 | 100.20 | -84.18 | -69.72 | -34.15 | -62.50 | -35.59 | -16.69 | -51.78 | -6.46 | -59.20 | -58.66 |
Current Ratio |
3.2 | 1.8 | 0.7 | 2.7 | 5.3 | 6.8 | 4.6 | 8.7 | 9.3 | 5.6 | 15.2 | 4.3 | 4.9 |
DSO |
- | 16.5 | 51.5 | 42.8 | 82.9 | 68.0 | 70.0 | 122.7 | 62.3 | - | - | - | - |
DIO |
- | - | 133.1 | 98.4 | 176.7 | 78.4 | 32.7 | 63.8 | 96.1 | - | - | - | - |
DPO |
- | - | 236.2 | 165.6 | 92.2 | 190.0 | 48.8 | 46.2 | 321.9 | - | - | - | - |
Операционный цикл |
- | 16.5 | 184.6 | 141.2 | 259.6 | 146.4 | 102.7 | 186.5 | 158.4 | - | - | - | - |
Финансовый цикл |
- | 16.5 | -51.6 | -24.4 | 167.4 | -43.6 | 54.0 | 140.3 | -163.5 | - | - | - | - |
Все данные представлены в валюте USD
Мультипликаторы поквартально AcelRx Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.13 | -0.15 | -0.16 | - | -0.08 | -0.4 | -0.75 | - | -0.94 | 8.58 | -1.19 | - | -1.4 | -0.08 | -0.08 | - | -0.1 | -0.08 | -0.2 | -0.18 | -0.16 | -0.16 | -0.17 | -0.18 | -0.21 | -0.2 | -0.23 | -0.2 | -0.28 | -0.29 | -0.34 | -0.21 | -0.25 | -0.24 | -0.24 | -0.24 | 0.11 | -0.2 | -0.23 | -320 | 20 | -240 | -220 | 0.41 | -0.26 | -0.47 | -0.34 | -0.41 | -0.38 | -0.35 | -0.36 | -0.33 | -0.3 | -0.25 | -0.3 |
EBITDA per Share |
- | - | - | - | - | - | -0.47 | - | -0.72 | -1.73 | -0.03 | - | -1.19 | -0.08 | -0.08 | - | -0.09 | -0.07 | -0.19 | - | -0.16 | -0.16 | -0.15 | - | -0.15 | -0.13 | -0.16 | - | -0.16 | -0.2 | -0.26 | - | -0.14 | -0.16 | -0.18 | - | 0.19 | -0.16 | -0.25 | - | -0.11 | 0.01 | - | - | 0.01 | 0.01 | - | - | 0.02 | 0.02 | 0.01 | - | 0.02 | 0.01 | 0.01 |
ROE % |
-96.46 | -69.09 | -80.98 | -106.60 | -131.40 | -148.78 | 106.38 | 211.08 | 230.54 | 274.80 | 88.97 | 79.63 | 95.65 | 92.20 | 76.68 | 56.43 | 91.26 | 105.98 | 124.09 | 128.54 | -201.55 | -525.21 | -803.03 | -1108.61 | -786.26 | -457.69 | -174.07 | 141.08 | 295.42 | 473.42 | 645.48 | 808.64 | 595.38 | 397.04 | 162.35 | -73.68 | -71.45 | -85.32 | -81.12 | -71.49 | -17.58 | -34.04 | -35.22 | -32.02 | -87.40 | -97.73 | -95.14 | -98.57 | -103.97 | -111.59 | -117.60 | -115.07 | -32.98 | -27.27 | -18.34 |
ROA % |
-50.93 | -40.81 | -50.07 | -61.50 | -75.47 | -83.61 | 66.93 | 99.86 | 88.27 | 90.65 | -47.61 | -34.22 | -47.69 | -49.57 | -47.16 | -47.46 | -63.24 | -63.71 | -67.33 | -58.28 | -52.91 | -49.31 | -44.47 | -39.12 | -41.78 | -48.67 | -57.21 | -68.18 | -64.77 | -58.95 | -52.76 | -43.16 | -41.73 | -26.36 | -22.23 | -19.09 | -26.83 | -30.02 | -35.29 | -38.59 | -6.45 | -17.21 | -20.83 | -21.29 | -53.75 | -57.06 | -52.36 | -51.71 | -51.01 | -51.81 | -52.33 | -49.22 | -14.11 | -11.66 | -7.85 |
ROCE % |
- | - | -37.41 | -74.82 | -99.18 | -86.13 | -127.08 | -52.42 | -32.35 | 12.08 | 80.86 | 81.37 | 97.58 | 93.72 | 78.15 | 56.90 | 89.57 | 106.04 | 126.04 | 94.68 | -124.65 | -376.66 | -577.10 | -581.94 | -557.67 | -314.07 | -118.66 | 84.57 | 234.00 | 359.15 | 487.86 | 465.04 | 486.49 | 358.52 | 178.06 | -37.50 | -48.37 | -80.69 | -56.16 | -10.86 | -10.86 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 2.0 | 2.3 | 3.2 | 4.7 | 2.4 | 2.2 | 1.9 | 2.3 | 2.4 | 0.7 | 0.7 | 0.6 | 0.7 | 0.8 | 0.5 | 0.5 | 0.5 | 0.5 | 0.7 | 0.7 | 0.7 | 0.7 | 1.0 | 1.0 | 1.0 | 1.0 | 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 0.9 | 0.9 | 0.9 | 1.4 | 1.4 | 1.4 | 1.4 | 2.2 | 2.2 | 2.2 | 2.2 | 3.0 | 3.0 | 3.0 | 3.0 | 2.1 | 2.1 | 2.1 | 2.1 | 1.8 | 1.8 | 1.8 | 1.8 |
DSO |
- | - | - | - | - | - | - | - | 78.8 | 43.9 | 35.5 | - | 6.3 | 78.5 | 115.5 | - | 42.4 | 19.8 | 126.1 | 83.0 | 64.8 | 41.9 | 82.8 | 7.3 | 11.9 | 5.5 | 210.4 | 189.0 | 94.1 | 52.6 | 108.1 | 82.7 | 158.1 | 117.5 | 137.5 | 173.3 | 19.4 | 155.8 | 828.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | 142.3 | 101.3 | 125.5 | - | 303.4 | 122.0 | 133.6 | - | 80.2 | 108.3 | 148.6 | - | 140.0 | 166.1 | 153.9 | - | 89.1 | 104.0 | 74.1 | - | 43.0 | 24.6 | 34.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | 353.1 | 266.4 | 281.4 | - | 433.3 | 227.1 | 262.0 | - | 134.9 | 182.3 | 134.6 | - | 73.1 | 86.7 | 140.6 | - | 215.9 | 252.2 | 143.1 | - | 64.0 | 36.7 | 33.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Операционный цикл |
- | - | - | - | - | - | - | - | 221.2 | 145.2 | 161.0 | - | 309.7 | 200.5 | 249.0 | - | 122.5 | 128.1 | 274.7 | 83.0 | 204.8 | 208.0 | 236.7 | 7.3 | 100.9 | 109.5 | 284.6 | 189.0 | 137.1 | 77.2 | 142.5 | 82.7 | 158.1 | 117.5 | 137.5 | 173.3 | 19.4 | 155.8 | 828.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Финансовый цикл |
- | - | - | - | - | - | - | - | -131.9 | -121.2 | -120.5 | - | -123.6 | -26.5 | -13.0 | - | -12.4 | -54.2 | 140.1 | 83.0 | 131.8 | 121.3 | 96.1 | 7.3 | -115.0 | -142.7 | 141.5 | 189.0 | 73.0 | 40.5 | 109.5 | 82.7 | 158.1 | 117.5 | 137.5 | 173.3 | 19.4 | 155.8 | 828.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Все данные представлены в валюте USD